|Product||Target||Indication||Lead OpPreclinPhase 1Phase 2Phase 3|
type 1 receptor
|Acute Heart Failure||intravenous|
|Moderate to Severe Pain||oral|
|Parkinson's, Migraine, Neuropathic Pain|
TRV027 is an intravenous drug for the treatment of acute heart failure (AHF) in combination with standard diuretic therapy, and is currently being investigated in a Phase 2 clinical trial. TRV027 is a β-arrestin biased ligand of the angiotensin II type 1 receptor (AT1R). Forest Laboratories Inc. (NYSE:FRX) has an exclusive option to license TRV027.
Dr. Michael Lark, CSO, and Ms. Kathy Goin, VP, Clinical Operations, will be attending the European Society of Cardiology Meeting in Barcelona, Spain on August 29 – September 3, 2014.
Copyright © Trevena, Inc.